A number of firms have modified their ratings and price targets on shares of Zymeworks (NASDAQ: ZYME) recently:
- 9/3/2026 – Zymeworks had its price target raised by JPMorgan Chase & Co. from $31.00 to $33.00. They now have an “overweight” rating on the stock.
- 8/26/2026 – Zymeworks was given a new $32.00 price target by Deutsche Bank Aktiengesellschaft.
- 8/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/26/2026 – Zymeworks had its price target raised by Citigroup Inc. from $37.00 to $38.00. They now have a “buy” rating on the stock.
- 8/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $32.00 price target on the stock.
- 8/26/2026 – Zymeworks had its price target raised by HC Wainwright from $51.00 to $55.00. They now have a “buy” rating on the stock.
- 8/10/2026 – Zymeworks had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $44.00 price target on the stock, up from $40.00.
- 8/10/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup Inc..
- 8/7/2026 – Zymeworks was given a new $46.00 price target by Stifel Nicolaus.
- 8/7/2026 – Zymeworks had its price target raised by Wells Fargo & Company from $37.00 to $40.00. They now have an “overweight” rating on the stock.
- 8/7/2026 – Zymeworks had its price target raised by Truist Financial Corporation from $31.00 to $32.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Zymeworks had its price target raised by HC Wainwright from $46.00 to $51.00. They now have a “buy” rating on the stock.
Zymeworks Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company uses its proprietary Azymetric and EFECT antibody-engineering platforms to design multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates intended to address complex disease biology.
Zymeworks’ leading product is zanidatamab, a bispecific antibody targeting HER2. In the United States, zanidatamab is marketed as Ziićhera for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.
Read More
- Five stocks we like better than Zymeworks
- 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.
